Blockchain Registration Transaction Record

BioCorRx Launches Phase 1 Trial for Long-Acting Naltrexone Implant

BioCorRx begins Phase 1 trial for BICX104, a 3-month naltrexone implant for addiction treatment. Study compares implant with/without bupropion against Vivitrol injection.

This development represents a potential breakthrough in addiction treatment that could significantly improve patient outcomes and adherence. Current extended-release naltrexone treatments require monthly injections, which can be challenging for patients struggling with substance use disorders who may miss appointments or discontinue treatment. A three-month implant could provide more consistent medication delivery, potentially reducing relapse rates and improving recovery success. The combination with bupropion is particularly interesting, as this could address both opioid and stimulant dependencies simultaneously, which is crucial given the rising prevalence of polysubstance use. For healthcare systems, longer-acting treatments could reduce administrative burdens and costs associated with frequent clinic visits. Most importantly, for the millions affected by substance use disorders worldwide, this innovation could mean more effective, convenient treatment options that fit better into their lives, potentially saving lives and reducing the devastating personal and societal impacts of addiction.